Evaluation of Potential Adverse Effects of Gender‐Affirming Hormonal Therapy; Findings from the Spanish Pharmacovigilance System Database
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.70052 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Elena María Pérez-López und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department Sevilla, University Hospital Virgen del Rocío, Andalucía, ES. Hauptthemen laut MEDLINE: Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Hormone Replacement Therapy, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
The Spanish Pharmacovigilance System for Medicines for Human Use (SEFV‐H) is responsible for recording and evaluating adverse reactions suspected to be due to medicines. The aim of this study was to review all reports of suspected adverse drug reactions (ADRs) in the SEFV‐H database derived from the gender‐affirming hormone therapy (GAHT). For this purpose, we consulted the Andalusian Centre for Pharmacovigilance (CAFV) and used three search algorithms to select only those reports derived from hormone therapy used by trangender people. A total of 21 reports were obtained, 13 corresponding to masculinizing therapy with testosterone and 8 corresponding to feminizing therapy with estradiol and cyproterone acetate. Most of these reports were of non‐serious symptoms. Skin and subcutaneous tissue disorders, neoplasms, and psychiatric, vascular, gastrointestinal, and nervous system disorders were the most common suspected ADRs. The median age was 23.6 years for masculinizing therapy and 27 years for feminizing therapy. These data highlight the need for well‐designed studies specifically focused on transgender people undergoing hormone therapy. Such studies are essential to develop evidence‐based treatment guidelines tailored to this population and to provide accurate, population‐specific information about the potential health risks associated with gender‐affirming hormone use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Department Sevilla, University Hospital Virgen del Rocío, Andalucía, ES.
- Andalusian Centre of Pharmacovigilance, Sevilla-Spanish Agency for Medications and Health Products, Pharmacovigilance, Comunidad de Madrid, ES.
- Clinical Pharmacology Department Sevilla, University Hospital Virgen de la Macarena, Andalucía, ES.
Zitieren
APA
Pérez-López, E. M., Roldán, J. N., Rojas, L. M. H., Martín, C. M. J., Pérez, M. R., Kolly, M. N. M., García, A. M., Molina, M. E. S., de Dios, A. F. M., López, L. M. C., & Máiquez Asuero, M. D. P. (2025). Evaluation of Potential Adverse Effects of Gender‐Affirming Hormonal Therapy; Findings from the Spanish Pharmacovigilance System Database. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70052
Vancouver
Pérez-López EM, Roldán JN, Rojas LMH, Martín CMJ, Pérez MR, Kolly MNM, et al. Evaluation of Potential Adverse Effects of Gender‐Affirming Hormonal Therapy; Findings from the Spanish Pharmacovigilance System Database. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70052
BibTeX
@article{PrezLpez2025,
author = {Pérez-López, Elena María and Roldán, Jorge Navarro and Rojas, Luisa María Herrera and Martín, Carmen María Jiménez and Pérez, Mercedes Ruiz and Kolly, María Nieves Merino and García, Asunción Mengíbar and Molina, María Esperanza Segura and de Dios, Ana Francisca Melcón and López, Luis Miguel Calderón and Máiquez Asuero, María Del Pilar},
title = {Evaluation of Potential Adverse Effects of Gender‐Affirming Hormonal Therapy; Findings from the Spanish Pharmacovigilance System Database},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.70052}
}
EUVIMED